{"entity":{"id":"nct07551596","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","aka":[],"tldr":"A phase 2 trial of balstilimab and botensilimab in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial is a phase 2, interventional study registered as NCT07551596 by National Cancer Institute (NCI), with a registry enrolment figure of 20 participants, started 2027-05-25 and due to reach its primary completion in 2029-08-28. Interventions recorded: Balstilimab; Biopsy Procedure; Biospecimen Collection; Botensilimab; Radiographic Examination. Conditions listed: Colorectal Adenocarcinoma; Stage II Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8. Primary outcome: Circulating tumor deoxyribonucleic acid (ctDNA) clearance. Colorectal eligibility wording from the registry: \"* Histological confirmation of colorectal cancer (adenocarcinoma) (CRC)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07551596","url":"https://clinicaltrials.gov/study/NCT07551596"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","mrd-testing"],"targets":[],"drugs":["balstilimab","botensilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07551596","phase":"2","setting":"A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)","sponsor":"National Cancer Institute (NCI)","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07551596/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}